Angiosarcoma is a highly malignancy of endothelial tumor and represents 1-2% of all soft
tissue sarcomas in humans. The aetiology of angiosarcoma is not clear but there are definite …

Abstract The 2016 Nobel Prize in Physiology or Medicine was awarded to the researcher
that discovered autophagy, which is an evolutionally conserved catabolic process which …

The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of
cancer therapies in the past years. However, only a limited fraction of patients benefit from …

Cutaneous angiosarcoma (cAS) is a rare malignant neoplasm with variable clinical
presentation. Although a distinct vascular tumour, cAS shares many overlapping …

Cutaneous angiosarcoma: update on biology and latest treatme... : Current Opinion in
Oncology Cutaneous angiosarcoma: update on biology and latest treatment : Current Opinion …

Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers)
decrease breast cancer progression, tumor metastasis, and patient mortality; however the …

The pharmacological class of β-blockers includes a plea of molecules with largely different
pharmacokinetic and pharmacodynamic characteristics with a protective effect that may …

Opinion statement Angiosarcomas are rare vascular neoplasms that are among the most
aggressive subtypes of soft tissue sarcomas. Surgical resection is often challenging even in …

Based largely on retrospective analyses and a handful of prospective case reports,
pharmacological inhibition of the beta adrenergic receptors using beta blockers has shown …

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor
antagonist (beta-blocker), with a range of actions which are of interest in an oncological …